Predisposition or Protection?

Mahmood, Kiran; Rashed, Eman; Oliveros, Estefanía; Chau, Vinh Q.; Hermle, Taylor; Jacobs, Samantha; Singhvi, Aditi; Parikh, Aditya; Pinney, S.

doi:10.1016/j.jaccas.2020.05.015

Cited by 17 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although they did not reveal major respiratory signs, COVID-19 PCR was performed as a routine procedure before hospitalization. The clinical profiles of our patients including WBC, CRP, D-dimer and cytokine levels seemed like the clinical profiles of infected LVAD patients [ 9 – 11 ]. The normal D-dimer values of these patients under triple anticoagulant-treatment according to our clinical protocol indicated that they were under protection against thromboembolic events.…”

Section: Discussionmentioning

confidence: 88%

“…In contrast, decompensated heart failure and low cardiac output state could make the patients more vulnerable to the infection and make it difficult to fight the infection. Although LVAD itself may play a pro-inflammatory role, by increasing cardiac output and improving clinical condition, it could reduce the inflammatory profile especially in contrast to pre-implant condition [ 9 ]. Our routine anticoagulation and anti-aggregant therapy after LVAD implantation include 300 mg acetylsalicylic acid per day, 75 mg clopidogrel per day, and warfarin with the target INR level around 2.0.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 ARDS in two patients with left ventricular assist device

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 2019 affected millions of people and caused pneumonia, acute respiratory distress syndrome and increased mortality worldwide. Data from multicenter studies showed that concomitant chronic diseases are associated with severe coronavirus disease. Patients with left ventricular assist device (LVAD) support may also be vulnerable to the disease. Some symptoms of COVID-19 infection like dyspnea and fatigue can overlap with heart failure or LVAD dysfunction. Careful evaluation should be made to diagnose and treat these patients. In these two cases with COVID-19, here we presented the first two patients supported with LVAD in Turkey.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

COVID-19 ARDS in two patients with left ventricular assist device

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Therefore we selected 18 chemical constituents from this plant to investigate their inhibition potential for COVID-19 M pro . Remdesivir is shown potential in treatment of Marburg virus, Paramyxoviridae (such as parainfluenza type 3, Nipah, Hendra, measles and mumps viruses) and Pneumoviridae (respiratory syncytial virus) (Ko et al 2020 ) that can represent possible treatment options against corona (Mahmood et al 2020 ) it was selected as standard drug (Pizzorno et al 2020 ).…”

Section: Resultsmentioning

confidence: 99%

Exploring the active constituents of Oroxylum indicum in intervention of novel coronavirus (COVID-19) based on molecular docking method

Shah¹,

Chaple²,

Arora

et al. 2021

Netw Model Anal Health Inform Bioinforma

View full text Add to dashboard Cite

The severe acute respiratory syndrome COVID-19 declared a global pandemic by WHO has become the present wellbeing worry to the whole world. There is an emergent need to search for possible medications. We report in this study a molecular docking study of eighteen Oroxylum indicum molecules with the main protease (M pro) responsible for the replication of SARS-CoV-2 virus. The outcome of their molecular simulation and ADMET properties reveal four potential inhibitors of the enzyme (Baicalein-7-O-diglucoside, Chrysin-7-O-glucuronide, Oroxindin and Scutellarein) with preference of ligand Chrysin-7-Oglucuronide that has the second highest binding energy (− 8.6 kcal/mol) and fully obeys the Lipinski's rule of five.

show abstract

“…30 Early clinical case reports have highlighted how LVAD patients respond to the cytokine storm of COVID-19. 34,35 Transplant patients pose other issues. Early in the postoperative period, patients undergo frequent routine endomyocardial biopsies and right heart catheterisations for surveillance for any signs of graft rejection.…”

Section: Advanced Heart Failure: Durable Left Ventricular Assist Devimentioning

confidence: 99%

Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach

et al. 2020

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a debilitating viral infection and, to date, 628,903 people have died from it, numbers that cannot yet be compared to the 50 million who died in the 1918 flu pandemic. As COVID-19 became better understood, cardiovascular manifestations associated with it were identified. This led to a complete healthcare restructuring with virtual clinics and changes to the triaging of critically ill patients. There are a lot of questions over how COVID-19 affects patients with heart failure (HF) as this condition is a leading cause of cardiovascular death. This review describes the cardiovascular implications of COVID-19 and new practices surrounding the use of telehealth to follow up and triage patients with HF. Current practices supported by medical societies, the role of angiotensin-converting enzyme inhibitors and, finally, a brief note regarding the management of advanced HF patients will also be discussed.

show abstract

Predisposition or Protection?

Cited by 17 publications

References 6 publications

COVID-19 ARDS in two patients with left ventricular assist device

COVID-19 ARDS in two patients with left ventricular assist device

Exploring the active constituents of Oroxylum indicum in intervention of novel coronavirus (COVID-19) based on molecular docking method

Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach

Contact Info

Product

Resources

About